This is a glucagon-like peptide-1 (GLP-1) agonist , meaning it imitates the hormone GLP-1 in your body
Melanie Jay, MD, MS, is a professor of medicine and population health at NYU Langone Health and a physician investigator specializing in obesity
Treatment should include supportive and other therapy as indicated by the patient's condition
The stack is built to support the signaling that naturally tapers, rather than to override it
Aging Cell 23 , e14102 (2024)
The Fat Loss Mechanism The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects: NNMT inhibition preserves SAM and NAD+ pools Increased NAD+ supports sirtuin activity and mitochondrial function Reduced lipogenesis adipocyte fatty acid synthesis is decreased Enhanced adipocyte metabolism improved adipose tissue function Selective effect on adipocytes relative sparing of other tissues Preclinical studies have shown that 5-amino-1MQ treatment in mice produces: Reduced body fat mass Improved insulin sensitivity Preserved lean mass Favorable effects on liver fat in diet-induced obesity models The Human Clinical Trials Picture As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature